Table 2.
Factors predictive of virological relapse.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Age (per year) | 1.022 (0.995–1.049) | 0.11 | ||
| Sex (Male vs. female) | 0.90 (0.44–1.81) | 0.76 | ||
| Cirrhosis | 0.48 (0.20–1.12) | 0.09 | ||
| FIB-4 | 0.99 (0.92–1.05) | 0.69 | ||
| ETV vs. LAM | 2.13 (0.99–4.59) | 0.053 | ||
| ALT (per ULN) | 1.000 (1.000–1.001) | 0.36 | ||
| Total bilirubin (per mg/dL) | 1.001 (0.936–1.071) | 0.97 | ||
| HBV DNA (per log IU/mL) | 1.44 (1.21–1.71) | <0.001 | 1.46 (1.21–1.76) | <0.001 |
| HBV genotype (C vs. B) | 0.59 (0.18–1.90) | 0.37 | ||
| HBsAg at baseline (per log IU/L) | 1.46 (1.08–1.98) | 0.015 | ||
| HBsAg at month 12 of treatment (per log IU/L) | 2.53 (1.43–4.46) | 0.001 | ||
| HBsAg at the end of treatment (per log IU/L) | 5.26 (2.22–12.47) | <0.001 | 5.67 (2.35–13.66) | <0.001 |
| HBsAg decline from baseline to end of treatment (per log IU/L) | 0.87 (0.65–1.17) | 0.36 | ||
| Treatment duration (per week) | 1.005 (1.000–1.009) | 0.034 | ||
| Consolidation duration (per week) | 1.004 (0.999–1.008) | 0.089 | ||
ALT: alanine aminotransferase, ETV: entecaivr, LAM: lamivudine, HR: hazard ratio, CI: confidence interval.